Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
chronic obstructive pulmonary disease (COPD)
Biotech
AirNexis swoops in with $200M series A for COPD asset
AirNexis has inked a deal potentially worth almost $1 billion with a China biopharma, securing rights to a clinical-stage COPD asset.
Gabrielle Masson
Jan 9, 2026 11:01am
GSK pens $750M deal for COPD-focused oligonucleotide in phase 1
Oct 28, 2025 6:45am
Expedition resupplies for ph. 2 COPD voyage with $165M series A
Oct 9, 2025 9:50am
Galvanize nets $100M, and a new CEO, to bring PFA to lung cancer
Sep 4, 2025 1:00pm
Expedition inks $645M Fosun deal to bring China asset to US
Aug 11, 2025 11:06am
Apreo Health nets $130M to develop lung scaffold for emphysema
Aug 8, 2025 11:30am
